Patent intelligence · US
US 12246014
Azetidine derivatives
Azetidine derivatives
Patent details — US 12246014
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 11, 2025
- Expiration
- Mar 6, 2045
- Applicant
- Ligand UK Development Limited
- Claims
- 10
- CPC classes
- A61K, A61K31/397, A61K31/4427, A61K31/4439
Quick answer
US 12246014 (Azetidine derivatives) is held by Ligand UK Development Limited. Status: granted. Granted Mar 11, 2025. Expires Mar 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Ligand UK Development Limited
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/397, A61K31/4427, A61K31/4439, A61K31/495, A61K31/497
More from Ligand UK Development Limited
Related pharmaceutical patents in our USPTO index.
-
US 12403087
Topical antiviral compositions, delivery systems, and methods of using the same
granted -
US 12319651
Crystalline forms and methods of producing crystalline forms of a compound
granted -
US 12208071
Glucagon receptor antagonists
granted -
US 12123012
Methods and compositions for nucleic acid and protein payload delivery
granted -
US 11970482
Acetal compounds and therapeutic uses thereof
granted -
US 11952364
TRK inhibitors useful as anticancer drugs
granted -
US 11773110
Heterocycle amines and uses thereof
granted
Frequently asked questions
What is US patent 12246014?
US 12246014 (Azetidine derivatives) is held by Ligand UK Development Limited. Status: granted. Granted Mar 11, 2025. Expires Mar 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12246014?
Ligand UK Development Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 133 pharmaceutical patents for this assignee.
When does US 12246014 expire?
Our index shows an expiration date of Mar 6, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.